🇺🇸 FDA
Patent

US 11976109

Neutralizing antibodies to ebola virus glycoprotein and their use

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11976109 (Neutralizing antibodies to ebola virus glycoprotein and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K48/005, A61P